Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yuanbin Chen

Showing results (81-90 of 99) with videos related to

Pageof 10
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung CancerDavid R Spigel, Afshin Dowlati, Yuanbin Chen, et al.
Nature Communications|April 20, 2022
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived modelsDelphine Lissa, Nobuyuki Takahashi, Parth Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2020
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III studyJonathan W Goldman, Marina Chiara Garassino, Yuanbin Chen, et al.
Clinical Lung Cancer|August 31, 2025
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN StudyNiels Reinmuth, Jonathan W Goldman, Yuanbin Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 8, 2019
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II StudyAnish Thomas, Rasa Vilimas, Christopher Trindade, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC TrialSilvia Novello, Ying Cheng, David Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational BurdenLuis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialAnne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
Lancet (London, England)|October 9, 2019
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialLuis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
Pageof 10

Showing results (81-90 of 99) with videos related to

Sort By:
Pageof 10
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 22, 2024
RESILIENT Part 2: A Randomized, Open-Label Phase III Study of Liposomal Irinotecan Versus Topotecan in Adults With Relapsed Small Cell Lung CancerDavid R Spigel, Afshin Dowlati, Yuanbin Chen, et al.
Nature Communications|April 20, 2022
Heterogeneity of neuroendocrine transcriptional states in metastatic small cell lung cancers and patient-derived modelsDelphine Lissa, Nobuyuki Takahashi, Parth Desai, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 6, 2014
A phase I/II trial of belinostat in combination with cisplatin, doxorubicin, and cyclophosphamide in thymic epithelial tumors: a clinical and translational studyAnish Thomas, Arun Rajan, Eva Szabo, et al.
Lung Cancer (Amsterdam, Netherlands)|September 22, 2020
Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III studyJonathan W Goldman, Marina Chiara Garassino, Yuanbin Chen, et al.
Clinical Lung Cancer|August 31, 2025
Durvalumab Plus Platinum-Etoposide in Extensive-Stage Small-Cell Lung Cancer: Outcomes in Age, Sex, and Platinum Subgroups From the Phase 3 CASPIAN StudyNiels Reinmuth, Jonathan W Goldman, Yuanbin Chen, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 8, 2019
Durvalumab in Combination with Olaparib in Patients with Relapsed SCLC: Results from a Phase II StudyAnish Thomas, Rasa Vilimas, Christopher Trindade, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 1, 2026
Patient-Reported Outcomes with Consolidation Durvalumab Versus Placebo Following Concurrent Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer: Results from the Phase 3 ADRIATIC TrialSilvia Novello, Ying Cheng, David Spigel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 6, 2023
Durvalumab ± Tremelimumab + Platinum-Etoposide in Extensive-Stage Small Cell Lung Cancer (CASPIAN): Outcomes by PD-L1 Expression and Tissue Tumor Mutational BurdenLuis Paz-Ares, Marina Chiara Garassino, Yuanbin Chen, et al.
Lung Cancer (Amsterdam, Netherlands)|August 7, 2025
Intracranial activity of sotorasib vs docetaxel in pretreated KRAS G12C-mutated advanced non-small cell lung cancer from a global, phase 3, randomized controlled trialAnne-Marie C Dingemans, Konstantinos Syrigos, Lorenzo Livi, et al.
Lancet (London, England)|October 9, 2019
Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trialLuis Paz-Ares, Mikhail Dvorkin, Yuanbin Chen, et al.
Pageof 10